CYP2C19*17 is associated with decreased breast cancer risk
Tóm tắt
Từ khóa
Tài liệu tham khảo
Key TJ, Allen NE, Spencer EA, Travis RC (2002) The effect of diet on risk of cancer. Lancet 360:861–868. doi: 10.1016/S0140-6736(02)09958-0
Folkerd EJ, Martin LA, Kendall A, Dowsett M (2006) The relationship between factors affecting endogenous oestradiol levels in postmenopausal women and breast cancer. J Steroid Biochem Mol Biol 102:250–255. doi: 10.1016/j.jsbmb.2006.09.024
Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S et al (2008) Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat 108:137–149
Cheng ZN, Shu Y, Liu ZQ, Wang LS, Ou-Yang DS, Zhou HH (2001) Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin 22:148–154
Cribb AE, Knight MJ, Dryer D, Guernsey J, Hender K, Tesch M et al (2006) Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomarkers Prev 15:551–558. doi: 10.1158/1055-9965.EPI-05-0801
Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T et al (1998) Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129:1027–1030
Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Iida T et al (2002) Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72:453–460. doi: 10.1067/mcp.2002.127637
Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T (2004) Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 5:181–202. doi: 10.1517/phgs.5.2.181.27483
Kawamura M, Ohara S, Koike T, Iijima K, Suzuki J, Kayaba S et al (2003) The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 17:965–973. doi: 10.1046/j.1365-2036.2003.01539.x
Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I et al (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442–473. doi: 10.1038/sj.mp.4001494
Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM et al (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187–5193. doi: 10.1200/JCO.2007.12.2705
De Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H et al (1995) Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 58:404–411. doi: 10.1016/0009-9236(95)90053-5
De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–598
Roddam PL, Rollinson S, Kane E, Roman E, Moorman A, Cartwright R et al (2000) Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics 10:605–615. doi: 10.1097/00008571-200010000-00004
Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L et al (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103–113. doi: 10.1016/j.clpt.2005.10.002
Justenhoven C, Hamann U, Pesch B, Harth V, Rabstein S, Baisch C et al (2004) ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population. Cancer Epidemiol Biomarkers Prev 13:2059–2064
Justenhoven C, Pierl CB, Haas S, Fischer HP, Baisch C, Hamann U et al (2007) The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer. Breast Cancer Res Treat. doi: 10.1007/s10549-007-9762-x
Pesch B, Ko Y, Brauch H, Hamann U, Harth V, Rabstein S et al (2005) Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol 20:699–711. doi: 10.1007/s10654-005-0032-0
Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265. doi: 10.1093/bioinformatics/bth457
Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J, Siuda A, Starzynska T, Drozdzik M (2006) Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 62:877–880. doi: 10.1007/s00228-006-0183-2
Beral V (2003) Breast cancer and hormone-replacement therapy in the million women study. Lancet 362:419–427. doi: 10.1016/S0140-6736(03)14596-5
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288:321–333. doi: 10.1001/jama.288.3.321